Search

Background. A key challenge in the treatment of advanced non-small-cell lung cancer (NSCLC) is improving outcomes for patients infirst, second line and maintenance therapy. We analyzed group of patients with progression free survival 6 month in order to elicit predic-tors of long response to the therapy with erlotinib.Methods. Between 2005 and 2013, we collect demographic data about 69 patients with NSCLC with PFS more than 6 month. In first linehave received 27 pts, second line - 36 pts and maintenance therapy - 6 pts. In most cases, data about mutation of EGFR was available.Results. We found possible correlation between level of response and duration of PFS. Duration of PFS in group with complete responsewas - 14,9 month, partial response - 12,9 month, stable disease - 12 month. Cohort of patients with the best response and longest PFSconsist of those with EGFR mutations, women and never or light smokers. We found 6 patients without EGFR mutation, in 5 of them thebest response was durable stable disease and in one - partial response.Conclusion. There are data supporting strong correlation between EGFR mutation status and objective response and duration of PFS inpatients treated with erlotinib. Patient without EGFR mutation have a real chance to reach long lasting stable disease in maintenance andsecond line therapy. Simple clinical characteristic, such as smoking status, gender and tumor histology can be used for selection patientsfor therapy with erlotinib.